Tuesday, 19 Nov 2019

You are here

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

SSc patients wwith active or painful indeterminate DUs were enrolled in a -blind, randomized, placebo-controlled, proof-of-concept trial. Patient were treated with placebo or riociguat in individualized doses (maximum of 2.5 mg three times daily) during an 8-week titration period, followed by an 8-week stable dosing period. The primary endpoint was the week 16 change in net ulcer burden (NUB), analyzed using ANCOVA. 

Seventeen participants were enroleld an 8 received placebo and 9 riociguat. Baseline characteristics were comparable between the treatment groups.

At baseline ulcers (NUB) wwere the same in the placebo (2.5) and riociguat (2.4) groups. But there was no significant treatment difference in NUB after 16 weeks of therapy. (adjusted mean treatment difference − 0.24, 95% CI (− 1.46, 0.99), p = 0.70).

Four participants experienced five serious AE (four in riociguat and one in placebo); none was considered related to study medication.

Six participants in each group transitioned to the open-label extension and thos in the riociguat-riociguat arm had complete healing of their DUs.

THese data suggest that long term (not short term) riociguat therapy is necessry to reduce the number of DU net burden in SSc  patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Part 1:  The “P” in Prednisone stands for Poison...and Other Pearls

Everyone has life hacks.  Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing. If this rat encounters its neighbor, it will transmit that information so the second rat won’t make the same mistake.

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.